Stifel analyst Benjamin Nolan downgrades Costamare (NYSE:CMRE) from Buy to Hold and lowers the price target from $12.5 to $11.
Chardan Capital Reiterates Buy on Krystal Biotech, Maintains $133 Price Target
Chardan Capital analyst Geulah Livshits reiterates Krystal Biotech (NASDAQ:KRYS) with a Buy and maintains $133 price target.